Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 110

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 110
---
                       
 timing, cost, regulatory approvals or other aspects of the commercial launch of Quilience 
 and Nolazol;                                                                              |

| ● | submission                                                                                 
 of a Marketing Authorisation Application and New Drug Application with the EMA and FDA for 
 Quilience, Nolazol, and or any of our pipeline drugs, respectively;                        |

| ● | completion                                                                                       
 and receiving favorable results of clinical trials for Quilience, Nolazol, and or any of         
 our pipeline drugs;                                                                              |
| ● | issuance                                                                                         
 of patents to us by the U.S. Patent and Trademark Office and other governmental patent agencies; |

| ● | new                                    
 issuances of orphan drug designations; |

| ● | the                                                                                     
 overall global political and economic environment in the countries in which we operate; |

| ● | the                                                                                              
 development and approval of the use of mazindol for additional indications other than narcolepsy 
 and attention deficit hyperactivity disorder, or ADHD;                                           |

| ● | the                                                                                         
 development and commercialization, if any, of any other product candidates that we may seek 
 to develop;                                                                                 |

| ● | the                                                                                               
 use of mazindol controlled release for treatment of additional indications other than narcolepsy, 
 idiopathic hypersomnia and ADHD; and                                                              |

| ● | the ability of our management                                                                                                     
 team to lead the development of our product candidates, conclude a strategic partnership deal for Mazindol or any of our pipeline 
 compounds.                                                                                                                        |

These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in this in greater detail under the heading “Risk Factors” and elsewhere in this prospectus and the documents incorporated herein by reference. You should not rely upon forward-looking statements as predictions of future events.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.

<div align='center'>74

USE OF PROCEEDS</div>

We will not receive any proceeds from the sale of the Common Shares by the Selling